Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)

The following ESMO Clinical Practice Guidelines have been recently updated with a new treatment recommendation for the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC). The European Medicines Agency (EMA) has approved durvalumab for the treatment of patients with locally advanced, unresectable, stage III non-small-cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy whose...